Regenxbio (RGNX) Tops Q4 EPS by 45c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pre-Open Stock Movers 02/25: (ONCE) (CMTA) (QURE) Higher; (MDR) (CRON) (NBR) Lower (more...)
February 25, 2019 9:25 AM ESTPre-Open Movers
Spark Therapeutics (NASDAQ: ONCE) 120.9% HIGHER; announced today that it has entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per share in an all-cash transaction. This corresponds to a total equity value of approximately $4.8 billion on a fully diluted basis, inclusive of approximately $500 million of projected net cash expected at close. The per share price represents a premium of 122 percent to Sparks closing price on Feb. 22, 2019. The merger agreement has been unanimously approved by the boards of both Spark and... More
Evercore ISI Upgrades Regenxbio Inc. (RGNX) to Outperform
February 25, 2019 2:38 AM ESTEvercore ISI analyst Josh Schimmer upgraded Regenxbio Inc. (NASDAQ: RGNX) from In Line to Outperform.
For an analyst ratings summary and ratings history on Regenxbio Inc. click here. For more ratings news on Regenxbio Inc. click here.
Shares of Regenxbio Inc. closed at $46.50 yesterday.
... More